Protalix BioTherapeutics, Inc. announced that it has achieved proof of concept results in an animal study conducted as part of its Acetylcholinesterase Program. The Acetylcholinesterase (AChE) Program is being conducted under the agreement the Company entered into with the Yissum Research and Development Company, the technology transfer arm of the Hebrew University of Jerusalem and the Boyce Thompson Institute, Inc., which is affiliated with Cornell University, the execution of which was reported by the Company on August 8, 2007. In the animal study conducted by the Company, the plant cell expressed form of the Acetylcholinesterase protein demonstrated full protection from organophosphate poisoning, simulating the capacity of the plant cell expressed Acetylcholinesterase protein to treat nerve gas and pesticide poisoning. Based on these positive preliminary results, Protalix has extended its agreement with Yissum to include a collaborative research program that will be conducted in the laboratory of Professor Hermona Soreq, a world leader in the field of Acetylcholinesterase research and Dean of the Faculty of Science at the Hebrew University of Jerusalem.

Dr. David Aviezer, President and Chief Executive Officer of the Company said, "This is another important milestone in the development of what we believe will be an important therapeutic protein. It demonstrates not only the clinical potential of Acetylcholinesterase but also the capacity of our ProCellEx plant cell expression system to generate a broad spectrum of human recombinant therapeutic proteins."

Nava Swersky Sofer, President and Chief Executive Officer of Yissum added, "We are pleased to see this significant scientific proof of concept and look forward to continuing the collaboration with Protalix toward commercializing the discoveries made by Professor Soreq and her team and bringing relief to patients around the world."

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company. Its goal is to become a fully integrated biopharmaceutical company focused on the development and commercialization of proprietary recombinant therapeutic proteins to be expressed through its proprietary plant cell based expression system. Protalix's ProCellEx presents a proprietary method for the expression of recombinant proteins that Protalix believes is safe and scalable and will allow for the cost-effective, industrial-scale production of recombinant therapeutic proteins. Protalix is enrolling and treating patients in its pivotal phase III clinical trial in Israel, the United States and other locations for its lead product candidate, prGCD, for its enzyme replacement therapy for Gaucher disease, a lysosomal storage disorder in humans, and has reached an agreement with the United States Food and Drug Administration on the final design of the pivotal phase III clinical trial through the FDA's Special Protocol Assessment (SPA) process. Protalix is also advancing additional recombinant biopharmaceutical drug development programs.

About Yissum

Yissum the technology transfer company of the Hebrew University of Jerusalem -- was founded in 1964 to protect the University's intellectual property and commercialize it. Today, more than $1 Billion in annual sales are generated by products based on Hebrew University technologies licensed out by Yissum. Ranked among the top technology transfer companies in the world, Yissum has registered 6,000 patents covering 1,600 inventions, licensed 450 technologies and spun out 60 companies.